JD Health has received a vote of confidence from CLSA, with its target price elevated to HK$56. The research firm anticipates that JD Health's total revenue will surge 23% year-over-year to reach RMB 34.8 billion in the first half of 2025. This growth is primarily fueled by the significant uptick in sales of nutritional supplements and medical devices during the 618 shopping festival. Additionally, the shift of proprietary drugs from hospital channels is bolstering drug demand. CLSA has also revised upwards its forecasts for JD Health's adjusted net profit in both 2025 and 2026, underpinned by the company's anticipated benefits from JD.com APP's user expansion strategy. Maintaining an "outperform" rating, CLSA notes that JD Health's robust revenue and profit growth, achieved through refined cost control measures, further cements its preeminent position in the pharmaceutical e-commerce landscape.